W
Wolfgang E. Berdel
Researcher at University of Münster
Publications - 656
Citations - 31014
Wolfgang E. Berdel is an academic researcher from University of Münster. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 80, co-authored 622 publications receiving 27709 citations. Previous affiliations of Wolfgang E. Berdel include University of Oldenburg.
Papers
More filters
Journal ArticleDOI
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.
Ping Ji,Sven Diederichs,Wenbing Wang,Sebastian Böing,Ralf Metzger,Paul M. Schneider,Nicola Tidow,Burkhard Brandt,Horst Buerger,Etmar Bulk,Michael Thomas,Wolfgang E. Berdel,Hubert Serve,Carsten Müller-Tidow +13 more
TL;DR: The identification of MALAT-1 emphasizes the potential role of noncoding RNAs in human cancer and contributes to the identification of early-stage NSCLC patients that are at high risk to develop metastasis.
Journal ArticleDOI
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W.K. Ng,Amanda Mitchell,James A. Kennedy,James A. Kennedy,James A. Kennedy,Weihsu C. Chen,Jessica McLeod,Narmin Ibrahimova,Andrea Arruda,Andreea C. Popescu,Vikas Gupta,Vikas Gupta,Vikas Gupta,Aaron D. Schimmer,Andre C. Schuh,Andre C. Schuh,Andre C. Schuh,Karen W.L. Yee,Karen W.L. Yee,Karen W.L. Yee,Lars Bullinger,Tobias Herold,Tobias Herold,Dennis Görlich,Thomas Büchner,Wolfgang Hiddemann,Wolfgang Hiddemann,Wolfgang E. Berdel,Bernhard Wörmann,Meyling Cheok,Claude Preudhomme,Hervé Dombret,Klaus H. Metzeler,Klaus H. Metzeler,Christian Buske,Bob Löwenberg,Peter J. M. Valk,Peter W. Zandstra,Mark D. Minden,John E. Dick,John E. Dick,Jean C.Y. Wang,Jean C.Y. Wang,Jean C.Y. Wang +43 more
TL;DR: The LSC17 score provides clinicians with a rapid and powerful tool to identify AML patients who do not benefit from standard therapy and who should be enrolled in trials evaluating novel upfront or post-remission strategies.
Journal ArticleDOI
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Berno Dankbar,Teresa Padró,R. Leo,Birgit Feldmann,Martin Kropff,Rolf M. Mesters,Hubert Serve,Wolfgang E. Berdel,Joachim Kienast +8 more
TL;DR: The effects of VEGF on marrow stroma are studied, focusing on the secretion of interleukin-6 (IL-6), a potent growth factor for myeloma cells and an inhibitor of plasma cell apoptosis, which suggests paracrine interactions between myelomas and marrow stromal cells triggered by VEGf and IL-6.
Journal ArticleDOI
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Beate Kempf-Bielack,Stefan S. Bielack,Heribert Jürgens,Detlev Branscheid,Wolfgang E. Berdel,G. Ulrich Exner,Ulrich Göbel,Knut Helmke,Gernot Jundt,Hartmut Kabisch,Mathias Kevric,Thomas Klingebiel,Rainer Kotz,Rainer Maas,Rudolf Schwarz,Michael Semik,Jörn Treuner,Andreas Zoubek,Kurt Winkler +18 more
TL;DR: Time to relapse and tumor burden correlate with postrelapse outcome in osteosarcoma and Chemotherapy, particularly chemotherapy with more than one agent, may contribute to limited improvements in outcome.
Journal ArticleDOI
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Masao Mizuki,Regina Fenski,Hartmut Halfter,Itaru Matsumura,Rainer Schmidt,Carsten Müller,Wolfram Grüning,Karsten Kratz-Albers,S Serve,Claudia Steur,Thomas Büchner,Joachim Kienast,Kanakura Y,Wolfgang E. Berdel,Hubert Serve +14 more
TL;DR: Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways.